Changes in serum afamin and vitamin E levels after selective LDL apheresis

Varga, V.; Lőrincz, Hajnalka; Szentpéteri, Anita; Juhász, Lilla; Serés, I.; Paragh, György; Balla, József; Harangi, Mariann

doi:10.1002/jca.21636

Cited by 7 publications

(4 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another protein that was reduced most efficiently by the TKM58 filter is afamin. In previous studies using regular LDL apheresis, afamin levels were only mildly reduced by about 10 % [21]. Afamin is a liver produced glycoprotein and early marker of metabolic syndrome [22].…”

Section: Discussionmentioning

confidence: 94%

Precision Medicine Approach for Cardiometabolic Risk Factors in Therapeutic Apheresis

Yin

Takov

Straube³

et al. 2022

Horm Metab Res

View full text Add to dashboard Cite

Lipoprotein apheresis (LA) is currently the most powerful intervention possible to reach a maximal reduction of lipids in patients with familial hypercholesterolemia and lipoprotein(a) hyperlipidemia. Although LA is an invasive method, it has few side effects and the best results in preventing further major cardiovascular events. It has been suggested that the highly significant reduction of cardiovascular complications in patients with severe lipid disorders achieved by LA is mediated not only by the potent reduction of lipid levels but also by the removal of other proinflammatory and proatherogenic factors. Here we performed a comprehensive proteomic analysis of patients on LA treatment using intra-individually a set of differently sized apheresis filters with the INUSpheresis system. This study revealed that proteomic analysis correlates well with routine clinical chemistry in these patients. The method is eminently suited to discover new biomarkers and risk factors for cardiovascular disease in these patients. Different filters achieve reduction and removal of proatherogenic proteins in different quantities. This includes not only apolipoproteins, C-reactive protein, fibrinogen, and plasminogen but also proteins like complement factor B (CFAB), protein AMBP, afamin, and the low affinity immunoglobulin gamma Fc region receptor III-A (FcγRIIIa) among others that have been described as atherosclerosis and metabolic vascular diseases promoting factors. We therefore conclude that future trials should be designed to develop an individualized therapy approach for patients on LA based on their metabolic and vascular risk profile. Furthermore, the power of such cascade filter treatment protocols may improve the prevention of cardiometabolic disease and its complications.

show abstract

Section: Discussionmentioning

confidence: 94%

Precision Medicine Approach for Cardiometabolic Risk Factors in Therapeutic Apheresis

Yin

Takov

Straube³

et al. 2022

Horm Metab Res

View full text Add to dashboard Cite

show abstract

“…In previous studies, plasma afamin levels were measured in patients suffering from secondary complications of already abnormal carbohydrate and lipid levels [ 10 , 11 , 22 ]. Furthermore, we previously observed moderately decreased circulating afamin concentrations—in line with HDL-C and ApoA1 levels—after LDL apheresis [ 23 ]. Therefore, our goal in this study was to measure afamin levels in morbidly obese patients without abnormal carbohydrate parameters.…”

Section: Introductionmentioning

confidence: 93%

Afamin Levels and Their Correlation with Oxidative and Lipid Parameters in Non-diabetic, Obese Patients

et al. 2022

Self Cite

View full text Add to dashboard Cite

Background: Afamin is a liver-produced bioactive protein and features α- and γ-tocopherol binding sites. Afamin levels are elevated in metabolic syndrome and obesity and correlate well with components of metabolic syndrome. Afamin concentrations, correlations between afamin and vitamin E, afamin and lipoprotein subfractions in non-diabetic, obese patients have not been fully examined. Methods: Fifty non-diabetic, morbidly obese patients and thirty-two healthy, normal-weight individuals were involved in our study. The afamin concentrations were measured by ELISA. Lipoprotein subfractions were determined with gel electrophoresis. Gas chromatography–mass spectrometry was used to measure α- and γ tocopherol levels. Results: Afamin concentrations were significantly higher in the obese patients compared to the healthy control (70.4 ± 12.8 vs. 47.6 ± 8.5 μg/mL, p < 0.001). Positive correlations were found between afamin and fasting glucose, HbA1c, hsCRP, triglyceride, and oxidized LDL level, as well as the amount and ratio of small HDL subfractions. Negative correlations were observed between afamin and mean LDL size, as well as the amount and ratio of large HDL subfractions. After multiple regression analysis, HbA1c levels and small HDL turned out to be independent predictors of afamin. Conclusions: Afamin may be involved in the development of obesity-related oxidative stress via the development of insulin resistance and not by affecting α- and γ-tocopherol levels.

show abstract

“…During apheresis, the level of protein-like components causing cardiovascular diseases is decreased in the serum; thus, the treatment has an evidently beneficial anti-atherosclerotic impact [ 27 ]. The serum levels of inflammatory cytokines and oxidative stress are reduced [ 28 ]. Vasodilation increases, and beneficial hemorheological changes are affected [ 29 , 30 ].…”

Section: Treatments Of Familial Hypercholesterolemiamentioning

confidence: 99%

The Importance of Arterial Stiffness Assessment in Patients with Familial Hypercholesterolemia

Kovács

Cseprekál

Lengyel

et al. 2022

JCM

Self Cite

View full text Add to dashboard Cite

Cardiovascular diseases are still the leading cause of mortality due to increased atherosclerosis worldwide. In the background of accelerated atherosclerosis, the most important risk factors include hypertension, age, male gender, hereditary predisposition, diabetes, obesity, smoking and lipid metabolism disorder. Arterial stiffness is a firmly established, independent predictor of cardiovascular risk. Patients with familial hypercholesterolemia are at very high cardiovascular risk. Non-invasive measurement of arterial stiffness is suitable for screening vascular dysfunction at subclinical stage in this severe inherited disorder. Some former studies found stiffer arteries in patients with familial hypercholesterolemia compared to healthy controls, while statin treatment has a beneficial effect on it. If conventional drug therapy fails in patients with severe familial hypercholesterolemia, PCSK9 inhibitor therapy should be administered; if these agents are not available, performing selective LDL apheresis could be considered. The impact of recent therapeutic approaches on vascular stiffness is not widely studied yet, even though the degree of accelerated athero and arteriosclerosis correlates with cardiovascular risk. The authors provide an overview of the diagnosis of familial hypercholesterolemia and the findings of studies on arterial dysfunction in patients with familial hypercholesterolemia, in addition to presenting the latest therapeutic options and their effects on arterial elasticity parameters.

show abstract

Changes in serum afamin and vitamin E levels after selective LDL apheresis

Cited by 7 publications

References 32 publications

Precision Medicine Approach for Cardiometabolic Risk Factors in Therapeutic Apheresis

Precision Medicine Approach for Cardiometabolic Risk Factors in Therapeutic Apheresis

Afamin Levels and Their Correlation with Oxidative and Lipid Parameters in Non-diabetic, Obese Patients

The Importance of Arterial Stiffness Assessment in Patients with Familial Hypercholesterolemia

Contact Info

Product

Resources

About